At Bessemer, we are fortunate to have the opportunity to mentor the next generation of investors through an apprenticeship-like model. Today, we are thrilled to celebrate the accomplishments of two such investors – Andrew Hedin and Mike Droesch – and announce their promotions to principal and vice president, respectively. Throughout their careers at Bessemer, both Andrew and Mike have made significant contributions to the success of the firm and cultivated strong relationships with entrepreneurs across different industries, providing them with the strategic partnership founders look for when building and scaling businesses.
Andrew joined Bessemer’s Boston office in 2015 as a senior associate and soon after was promoted to vice president focused on investing in biotechnology and healthcare technology companies. He has dedicated his career to healthcare investing, believing he will have the greatest impact on the broken healthcare industry by funding companies bringing new therapeutics to patients and novel technologies to the ecosystem. Before joining the Bessemer healthcare practice, Andrew spent three years at F-Prime Capital investing in biotech and healthcare companies as well as three years advising pharmaceutical and biotech companies at Leerink Partners.
“Healthcare entrepreneurs dedicate their careers to bettering patients’ lives, but it’s never easy. I look for tenacious founders who want to do well by doing good. With recent scientific and technical breakthroughs, I’m optimistic that a lot of ‘good’ is coming.” - Andrew Hedin
Andrew has sourced and spearheaded investments in Qventus, an AI-based software platform that optimizes patient flow across the hospital, Collective Medical, the nation’s most effective network for care collaboration, and Kymera Therapeutics, a biotech company pioneering a new approach to treating previously untreatable diseases. Today, he also serves as a board observer for many of our healthcare companies including, TScan Therapeutics, Bright Health, Artemis Health, Groups, AccuVein, and Docent Health. In his new role, as principal, Andrew will lead investments in startups across the healthcare ecosystem with a particular focus on expanding our biotech practice.
In 2017, Mike joined Bessemer as a senior associate in our New York City office focused on investing in promising developer tools, open source software, and B2B marketplace startups. Mike sourced and championed our Series A investment in automated IT support provider, Electric, and our seed investment in front-end test automation platform, Cypress.io. Over the following year, he worked closely with Cypress.io CEO, Drew Lanham, and Founder and CTO, Brian Mann, as they scaled the team and in June 2019, Mike and partner Bob Goodman led Cypress’ Series A with Mike joining the board of directors. Mike also serves as a board observer for Electric, ACV Auctions, Verodin (acquired by FireEye), Disco, Capsule8, Fuze, and Smashfly.
Before joining Bessemer, Mike spent time at Bessemer companies, Fuze and Insight Squared, and three years as a management consultant at Navigant, where he helped companies build new businesses around emerging energy and infrastructure technologies in the U.S. and the Middle East. As vice president, Mike will continue to focus on investing in promising entrepreneurs who are founding businesses with fundamental distribution advantages, whether that be through building developer tools with vibrant open source communities or scaling marketplace with innovative liquidity hacks.
“We see opportunities for modern B2B marketplaces to disrupt many of the largest industries on the planet. Doing so requires ambitious founders who know these industries intimately, but are also just crazy enough to believe they can uproot the entrenched incumbents in these highly relationship-driven markets. I am particularly excited about platforms that are both removing friction and solving the trust problems that have hampered prior generations of B2B marketplaces.” - Mike Droesch
Congratulations, Andrew and Mike! Bessemer thanks you for your dedication and all your contributions to the firm and our community of founders.